Experiences with
Chlorambucil110 public posts
Ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland.
SMC restriction: for use in patients who would not be considered for bendamustine therapy and who would receive chlorambucil-based therapy.
Arzerra (ofatumumab) PBS listed in Australia
[i]ARZERRA (ofatumumab) in combination with chlorambucil will be listed on the Pharmaceutical Benefits Scheme as of 01 Apr 2015 for patients with CLL [u]who have not received prior therapy and are inappropriate for fludarabine-based therapy[/u], GlaxoSmithKline has said.
Want to take advantage of all our features? Just log in!
or
What is the treatment for Sweet's syndrome?
Other treatments include tetracycline antibiotics; infliximab; immunoglobulin; methotrexate; chlorambucil; cyclophosamide; interferon alpha; anakinra.
Read more about treatment options @ http://helpforsweetssyndromeuk.wordpress.com/key-information/what-is-the-treatment-for-sweets-syndrome/
GAZYVA® (Obinutuzumab) gains TGA approval for 1st line treatment of CLL in combination with Chlorambucil in Australia
In the CLL11 GAZYVA study, GAZYVA + Chlorambucil:
* More than doubled Progression Free Survival (PFS) vs Chlorambucil alone (26.7 vs 11.1 months)
* Provided nearly 1-year improvement in PFS vs MabThera (Rituximab) + Chlorambucil (26.7 vs 15.2 months)
This follows FDA approval 7 months ago:
https:/
Australians - here's your opportunity to support the listing of GAZYVA (Obinutuzimab) on the PBS - Deadline is Wed 11th June!
GAZYVA + :
[i]
* More than doubled Progression Free Survival (PFS) vs Chlorambucil alone (26.7 vs 11.1 months)
* Provided nearly 1-year improvement in PFS vs MabThera (Rituximab) + Chlorambucil (26.7 vs 15.2 months)
[/i]
As the PBAC site says:
"Your comments are welcome whether you
Dr Sharman on Management of CLL in Elderly
Oncology on Management of CLL in Elderly/Frail patients on his blog:
http://www.cll-nhl.com/2014/06/management-of-cll-in-elderly-cll-asco.html
Just clicking through them will give you an appreciation of how the newer drugs are improving the outcome for older patients, including when partnered with Chlorambucil
Dr Peter Hillmen of Leeds, UK discusses the place for Idelalisib in CLL treatment (Patient Power Video)
[/i]
http://www.patientpower.info/video/where-a-pi3k-inhibitor-could-fit-in-for-cll
Interesting to hear that in contrast to the Patient Power introduction, in the UK, Dr Hillmen sees Idelalisib as likely to have a place with a chemotherapy backbone of Chlorambucil + Ofatumumab or Bendamustine + Ofatumumab
Obinutuzumab was approved for treatment naive patients, but in only in combination with chlorambucil.
Friends
Obinutuzumab was approved for treatment naive patients, but in only in combination with chlorambucil.
That is a very limited indication and I don't like that
You might want to read my blog commentary on the issues swirling around this FDA decision.
Marketing authorisation application submitted to the European Medicines Agency for the use of ofatumumab for first line treatment
The submission is based primarily on results from an international, multi-centre, randomised phase III study of ofatumumab in combination with chlorambucil versus chlorambucil alone in more than 400 patients with previously untreated CLL.
http://www.pharmabiz.com/NewsDetails.aspx?
Arzerra(R) (Ofatumumab) granted FDA 'Breakthrough Therapy Designation' for Previously Untreated CLL
Genmab A/S and GlaxoSmithKline plc (GSK) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Arzerra(r) (ofatumumab) in combination with chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior